Irish medical device company Neurent Medical has closed an oversubscribed €62.5m Series C financing round to drive commercial expansion, broaden clinical evidence and advance its product pipeline, according to EU-Startups.

The Galway-based firm develops NEUROMARK, a minimally invasive solution treating chronic rhinitis through posterior nasal nerve ablation.

The financing was led by MVM Partners, with significant participation from Sofinnova Partners, and included continued support from existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland.

Neurent Medical's Series C places it at the higher end of European MedTech fundraising in 2025-2026, highlighting investor confidence in companies developing clinically validated devices for chronic conditions.

Brian Shields, CEO of Neurent Medical, said, "I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in MedTech investing. This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most."

Kyle Dempsey, Partner at MVM Partners, said, "Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief. In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure."

Cedric Moreau, Partner at Sofinnova Partners, said, "Chronic rhinitis is a widespread and often overlooked condition affecting millions of patients with limited effective treatment options. We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth."

Explore how Neurent Medical is advancing chronic rhinitis treatment in the complete article.